Compare USCB & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USCB | ELDN |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.0M | 291.8M |
| IPO Year | 2021 | 2014 |
| Metric | USCB | ELDN |
|---|---|---|
| Price | $20.90 | $3.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $23.00 | $8.50 |
| AVG Volume (30 Days) | 59.0K | ★ 1.7M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | 7.26 | ★ 30.67 |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.46 | N/A |
| Revenue Next Year | $9.67 | N/A |
| P/E Ratio | $40.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.06 | $1.35 |
| 52 Week High | $20.93 | $4.60 |
| Indicator | USCB | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 71.56 | 57.41 |
| Support Level | $17.83 | $3.35 |
| Resistance Level | N/A | $4.09 |
| Average True Range (ATR) | 0.58 | 0.33 |
| MACD | 0.14 | 0.03 |
| Stochastic Oscillator | 98.53 | 50.00 |
USCB Financial Holdings Inc is a bank holding company. Through its banking subsidiary, it offers relationship-based banking products, services, and solutions to a diverse set of clients in the local markets it operates in and international clients with U.S. banking needs. The Group's products and services offerings mainly include traditional deposit products, including commercial and consumer checking accounts, money market deposit accounts, savings accounts, etc.; e-banking services; title insurance policies for real estate transactions; and a variety of lending products such as small business loans, commercial real estate loans, business credit cards, etc.; and others. Geographically, its primary banking market is South Florida.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.